THEMO
14.3.2024 08:01:33 CET | Business Wire | Press release
The smart thermostat technology of the Estonian-Finnish cleantech company Themo has passed the requirements for Fingrid's Frequency Containment Reserve in Finland. This means that the frequency of Finland's national electricity grid can in the future be balanced quickly and easily through the heating systems of all Finnish electrically heated households and other residential and accommodation spaces. Themo's smart thermostats save money for their users by optimizing electricity consumption while considering the current market price. In addition, the owners will now be compensated for the utilization of thermostats in the reserve market. Themo also secured a growth funding of 1.3 million euros for product development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240313357001/en/
Pictured from left: Joonas Rantala, Sales Director of Themo, Madis Uuemaa, CEO and Markus Perkkiö, CFO. (Photo: Business Wire)
Themo's core innovation is an efficient electricity optimization algorithm on which the company's smart thermostats are based. In addition to many other parameters such as time of day and weather forecast, the algorithm considers fluctuations in the price of electricity on the stock exchange when optimizing electric heating.
Themo thermostats can now also be used to balance the frequency of Fingrid's grid. The reserve market operated by Fingrid is used to adjust the grid to balance electricity consumption and production. Themo's technology can control many relatively low-power, standard electric heaters with a fast response time.
“We have successfully verified the operation of 1 MW of power mass under test conditions organized by Fingrid. To pass Fingrid's FCR-D market requirements, the reserve market supplier must be able to detect the frequency deviation and make the necessary adjustment itself within 7.5 seconds. With our sophisticated cloud solution, aggregation and adjustment of devices is possible in seconds," says Madis Uuemaa, CEO and technology developer at Themo.
Aggregated power from 20,000 smart thermostats balances the frequency of the grid
Frequency Containment Reserve for Normal Operation (FCR-N) and Frequency Containment Reserve for Disturbances (FCR-D) are active power reserves that are automatically controlled based on the frequency deviation. The Frequency Containment Reserve for Disturbances (FCR-D), the control test which Themo smart thermostats have now passed, maintains a frequency of at least 49.5 Hz or up to 50.5 Hz when the frequency deviates from the standard range. At equilibrium, the frequency is 50.0 Hz.
“In practice, this means that when a frequency deviation is detected, the algorithm automatically switches on all Themo smart thermostats for a short period of time, for instance 20 seconds. Switching on does not affect the heating of the home or heating costs, but with 20,000 electric heaters in the Finnish market alone, aggregated power has a significant balancing effect on the frequency. In addition, Fingrid will pay a compensation based on marginal pricing," says Uuemaa.
Themo's b2b customers involved in the reserve market
Intelligent and rapidly adjustable electrical innovations like Themo are key to the transition from fossil fuels to more sustainable energy solutions. New energy solutions such as solar and wind are more volatile for the grid. To balance the frequency deviations of the grid, reserves are needed and Fingrid will purchase them from the market it operates. Such reserves are for examples power plants, consumption targets, and energy storage facilities that change their output as needed.
“It is a great achievement and socially important that we can use the large reserves of existing electric heaters to balance the grid. In the past, balancing was done mainly by fossil power plants. The technology developed by Themo is an important part of future smart electricity grids," says Joonas Rantala, Sales Director at Themo.
Themo's b2b customers, such as Sato, Y-Foundation, Asuntosäätiö, rental housing companies owned by the largest Finnish cities, Holiday Club resorts, and some other companies offering rental housing and other types of accommodation or care services participated in the approved test. In the future, Themo's b2c customers will also be able to participate in the reserve market.
Themo manages around 10 MW under its current customer base. The aim is to manage 60 MW by the end of 2026.
EUR 1.3 million growth funding for product development
In addition to passing Fingrid's reserve market regulation test, Themo also secured EUR 1.3 million in growth funding for product development. This funding will strengthen Themo's position in the market and enable it to invest increasingly in smart energy solutions. The company's long-term goal is to secure emission-free and affordable electricity for everyone. With smart thermostats, customers can save up to 50% of electricity compared to manual thermostats. For a large rental property operators or hotels, financial savings can amount to tens of thousands of euros.
The lead investor in the funding round is Sunly, an Estonian company investing in renewable energy and modern technology. Sunly has already participated in Themo's previous funding rounds. The second largest investor is Finnish Indie Investments, owned by Heikki Nakari. Other Finnish angel investors such as Henry Nilert and Ali Omar are also involved.
Themo is an Estonian-Finnish cleantech company founded in 2014. Themo consists of the parent company Smart Load Solutions OÜ and its wholly owned Finnish subsidiary Themo Nordic Oy. The technology developed by Themo is an important part of the smarter electricity grid of the future. The company's long-term mission is to enable clean and affordable electricity for all. www.themo.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240313357001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
